JP2020524162A5 - - Google Patents

Info

Publication number
JP2020524162A5
JP2020524162A5 JP2019570491A JP2019570491A JP2020524162A5 JP 2020524162 A5 JP2020524162 A5 JP 2020524162A5 JP 2019570491 A JP2019570491 A JP 2019570491A JP 2019570491 A JP2019570491 A JP 2019570491A JP 2020524162 A5 JP2020524162 A5 JP 2020524162A5
Authority
JP
Japan
Prior art keywords
dosage form
saliva
composition according
acid
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019570491A
Other languages
English (en)
Japanese (ja)
Other versions
JP7297685B2 (ja
JP2020524162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037698 external-priority patent/WO2018236678A1/en
Publication of JP2020524162A publication Critical patent/JP2020524162A/ja
Publication of JP2020524162A5 publication Critical patent/JP2020524162A5/ja
Application granted granted Critical
Publication of JP7297685B2 publication Critical patent/JP7297685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019570491A 2017-06-20 2018-06-15 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 Active JP7297685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
US62/522,473 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (3)

Publication Number Publication Date
JP2020524162A JP2020524162A (ja) 2020-08-13
JP2020524162A5 true JP2020524162A5 (cg-RX-API-DMAC7.html) 2022-08-03
JP7297685B2 JP7297685B2 (ja) 2023-06-26

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570491A Active JP7297685B2 (ja) 2017-06-20 2018-06-15 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤

Country Status (13)

Country Link
US (4) US10500280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641759B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297685B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200018652A (cg-RX-API-DMAC7.html)
CN (1) CN110913853A (cg-RX-API-DMAC7.html)
AU (1) AU2018289284A1 (cg-RX-API-DMAC7.html)
BR (2) BR122021012549B8 (cg-RX-API-DMAC7.html)
CA (1) CA3067822C (cg-RX-API-DMAC7.html)
ES (1) ES2979335T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019015733A (cg-RX-API-DMAC7.html)
RU (1) RU2020101742A (cg-RX-API-DMAC7.html)
SG (1) SG11201912172YA (cg-RX-API-DMAC7.html)
WO (1) WO2018236678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
US20240189331A1 (en) * 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
EP4351525A1 (en) * 2021-06-09 2024-04-17 AGB-Pharma AB Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
US20110092602A1 (en) * 2008-04-25 2011-04-21 Nitin Shivcharan Laddha Rapidly disintegrating oral compositions of tramadol
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) * 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
ES2880618T3 (es) 2015-03-02 2021-11-25 Medlab Clinical U S Inc Sistemas de suministro transmucosa y transdérmico
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Similar Documents

Publication Publication Date Title
JP2018517715A5 (cg-RX-API-DMAC7.html)
RU2016151697A (ru) Расправляемая удерживаемая в желудке лекарственная форма
RU2020101742A (ru) Растворяющаяся во рту лекарственная форма мелатонина с подкисляющей добавкой, которая делает мелатонин растворимым в слюне
JP2016525572A5 (cg-RX-API-DMAC7.html)
JP2010504993A5 (cg-RX-API-DMAC7.html)
JP2013501718A5 (cg-RX-API-DMAC7.html)
NZ599594A (en) Fast dissolving solid dosage form
RU2008127490A (ru) Композиции и капсулы с устойчивыми гидрофильными слоями
JP2009538920A5 (cg-RX-API-DMAC7.html)
JP2018521985A5 (cg-RX-API-DMAC7.html)
JP2005528430A5 (cg-RX-API-DMAC7.html)
JP2014221827A5 (cg-RX-API-DMAC7.html)
US20200022919A1 (en) Compositions of midodrine and methods of using the same
CN113476421B (zh) 一种非布司他的控释组合物及其制备方法
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
JP2021529829A5 (cg-RX-API-DMAC7.html)
JP2010523678A5 (cg-RX-API-DMAC7.html)
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
JP2011520980A5 (cg-RX-API-DMAC7.html)
JP2016503803A5 (cg-RX-API-DMAC7.html)
JP2013523628A5 (cg-RX-API-DMAC7.html)
JP2015521647A5 (cg-RX-API-DMAC7.html)
TW201318650A (zh) 口崩片組成物
JP6517575B2 (ja) 積層錠剤
FI3261625T3 (fi) Kolmena pulssina vapauttavia stimulanttiformulaatioita